Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

9480	Companies
185543	Keywords
117939	Articles
99384	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 08/02/2024 at 16:05, 1 year 4 months ago

Elaine Elisabetsky, PhD, to Discuss Plant-Based Schizophrenia Treatments

Jaguar Health Magdalena Biosciences Schizophrenia Plant-based Medicine Ethnopharmacology
PRESS RELEASE

published on 08/02/2024 at 16:00, 1 year 4 months ago

Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy
Dr. Elisabetsky conducts research on plant-based medicines for mental health conditions. Jaguar out-licenses botanical drug for schizophrenia treatment to Magdalena Biosciences

Jaguar Health Magdalena Biosciences Schizophrenia Dr. Elisabetsky Plant-based Medicines
BRIEF

published on 06/26/2024 at 14:35, 1 year 5 months ago

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement

Crofelemer Jaguar Health Nasdaq Compliance OnTarget Trial Cancer Supportive Care
PRESS RELEASE

published on 06/26/2024 at 14:30, 1 year 5 months ago

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement
JAGX's securities remain listed and traded on Nasdaq as Jaguar announces regaining compliance with Nasdaq's bid price requirement. Updates on cancer supportive care drug crofelemer OnTarget trial results expected by July 23, 2024

Crofelemer Nasdaq Jaguar Health OnTarget Trial JAGX
BRIEF

published on 06/21/2024 at 22:20, 1 year 5 months ago

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Crofelemer Podcast Jaguar Health OnTarget Trial World Rainforest Day
PRESS RELEASE

published on 06/21/2024 at 22:15, 1 year 5 months ago

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders
Jaguar Health, Inc. to report pivotal phase 3 OnTarget trial results for cancer supportive care drug crofelemer by July 23, 2024. Investor webcast and podcast interview updates included

Crofelemer Investor Webcast Jaguar Health OnTarget Trial Cancer Supportive Care
BRIEF

published on 06/12/2024 at 14:35, 1 year 5 months ago

Jaguar Health to Announce Pivotal Phase 3 OnTarget Trial Results by July 23, 2024

Crofelemer Investor Webcast Jaguar Health Phase 3 OnTarget Trial Cancer Supportive Care
PRESS RELEASE

published on 06/12/2024 at 14:30, 1 year 5 months ago

Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024
Jaguar Health, Inc. to discuss updates on cancer supportive care portfolio in investor webcast, focusing on CTD and oral mucositis. Details on pivotal phase 3 OnTarget trial for crofelemer

Investor Webcast Jaguar Health Inc. Oral Mucositis Cancer Supportive Care CTD
BRIEF

published on 06/07/2024 at 22:20, 1 year 5 months ago

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Restricted Stock Units Compensation Nasdaq Jaguar Health
PRESS RELEASE

published on 06/07/2024 at 22:15, 1 year 5 months ago

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health, Inc. granted 1,111 RSUs to a new employee, subject to one-year vesting. The RSUs were approved by the Compensation Committee

Restricted Stock Units Employee Benefits Jaguar Health Inc. RSUs Compensation Committee

Accesswire

Published on 12/05/2025 at 20:25, 31 minutes ago

The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 41 minutes ago

When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 6 minutes ago

Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 1 hour 36 minutes ago

The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 2 hours 11 minutes ago

Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 18:58, 1 hour 58 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 2 hours 29 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 2 hours 40 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:51, 3 hours 4 minutes ago

Issue of Equity
Published on 12/05/2025 at 17:46, 3 hours 10 minutes ago

Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds

Les Echos

Published on 12/05/2025 at 17:18, 3 hours 38 minutes ago

The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 45 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 12 hours 11 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 1 day 2 hours ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 1 day 3 hours ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL

View all LES ECHOS COMFI WIRE